CNSystems Appoints the Sage Group to Identify Strategic Partnerships for its Non Invasive Hemodynami

Graz, Austria, Cambridge UK, and Clinton NJ – January 2015 – CNSystems announces that following an internal strategic assessment, it has launched a global program to enter into one or more strategic alliances for its non-invasive continuous hemodynamic monitoring systems. The Sage Group has been appointed by CNSystems to assist the company in this endeavor. The objective is to partner with well-established companies which will work with the CNSystems-technology to further the commercial traction CNSystems has already achieved and to expand commercialization into a wider range of markets so as to achieve market leadership in the emerging field of totally noninvasive hemodynamic monitoring with particular focus on the operating room.

Dr Juergen Fortin, CEO of CNSystems, said “With more than 3,500 units sold worldwide, CNSystems is poised to become the undisputed market leader in continuous non-invasive hemodynamic monitoring. Similarly to the market impact of pulse oximetry, the Company’s CNAP® technology has the potential for being sold into every operating theatre in the world! We are pleased to be working with The Sage Group to identify global strategic partners for our technology.”

CNSystems has established a strong pedigree and position of innovative leadership in the field of continuous non-invasive hemodynamic (HD) monitoring, as evidenced by over 400 clinical and scientific publications. The Company’s expertise in non-invasive hemodynamic monitoring has led to four key products which have global regulatory approval. CNSystems has sold more than 3,500 systems to date.

CNSystems has a strong product pipeline of products in the emerging market for totally non-invasive hemodynamic monitoring in the operating room. These are planned to receive all regulatory clearances by 2016.

The hemodynamic monitoring market is estimated to be $1.3 billion today with only a very small portion truly noninvasive. This creates a significant opportunity for CNSystems and its partner(s). The fundamental drivers of this emerging market are real and powerful: significantly fewer adverse effects, shorter hospital stays and improved patient care.

CNSystems has an exceptionally strong IP portfolio with 54 granted patents, 11 pending and long lifetimes remaining on key IP.

CNSystems has a highly experienced and competent management team. CNSystems has achieved all its technical and product developments, clinical and regulatory benchmarks, manufacturing/assembly operations and commercialization[BF1] .